QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: PASS in the EU Risk Management Plan

Test your understanding of the concepts covered by GVP Module VIII: PASS in the Risk Management Plan.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement correctly distinguishes evidence, scientific interpretation and an RMP decision?

The PASS directly makes the RMP decision through its statistical output. The RMP determines the scientific conclusion before the PASS is conducted. The PASS produces evidence, experts interpret it in context, and the organisation and regulators determine the resulting risk-management position. Scientific interpretation is unnecessary when the study has met its protocol objectives.

Question 2 of 10 A risk-minimisation effectiveness study shows that educational materials were distributed but prescribing behaviour did not improve. What is the most appropriate interpretation?

The measure was effective because implementation was documented. The measure was ineffective for all possible reasons, so no further analysis is needed. Implementation occurred, but the intended effect was not demonstrated; the organisation should assess whether the problem concerns implementation, intervention design or both. The result should be treated only as a routine adverse-event signal.

Question 3 of 10 Which sequence most accurately represents the evidence-to-decision chain described in the article?

PASS result, safety concern, protocol, RMP decision, safety specification. Safety concern or knowledge gap, pharmacovigilance objective, PASS, evidence, updated safety assessment, RMP decision. RMP decision, PASS, safety concern, routine pharmacovigilance, protocol. Risk-minimisation measure, final report, safety specification, study objective, signal detection.

Question 4 of 10 Which statement best explains why a completed PASS should not automatically be treated as obsolete?

Completed studies have no relationship to RMP lifecycle decisions. A completed study may still provide relevant evidence, support residual monitoring or require documented integration into the current strategy. The RMP must retain every study permanently without reassessment. A study becomes obsolete only when its database is closed.

Question 5 of 10 Which question is most useful when deciding whether an existing PASS should remain in the RMP?

Has the study always appeared in previous RMP versions? Is the study still the appropriate activity for a relevant current safety question, and can it still answer that question? Has the study generated a publication in a peer-reviewed journal? Has the study exhausted its budget?

Question 6 of 10 A PASS is completed and the final report is available. What is the most appropriate next governance step?

Automatically remove the study from all RMP documentation. Automatically reclassify the investigated risk as resolved. Perform a scientific impact assessment covering the safety specification, pharmacovigilance plan and relevant risk-minimisation measures. Wait until the next routine RMP cycle before reviewing the results.

Question 7 of 10 A study investigating an important potential risk does not confirm the anticipated association. Which interpretation is most appropriate?

The risk is definitively disproven because the primary analysis was negative. The result should be interpreted in light of power, outcome definition, exposure, data quality and residual uncertainty. The study has no value because it did not identify a new risk. The risk must remain unchanged because negative findings cannot affect an RMP.

Question 8 of 10 An inspector asks why a PASS is listed in the RMP, but the organisation cannot identify the safety concern or knowledge gap it addresses. What does this most strongly suggest?

The study is automatically invalid because its final report is unavailable. The RMP entry may have become an administrative listing rather than a meaningful representation of the pharmacovigilance strategy. The study must be a voluntary study rather than an imposed study. The safety specification is necessarily incorrect.

Question 9 of 10 How should PASS evidence generally relate to the PSUR?

The PSUR should ignore the study because the RMP is the only downstream interface. The PSUR should reproduce the PASS report without performing its own cumulative evaluation. Relevant study progress, results or implications should enter the appropriate aggregate reporting process and be evaluated for the PSUR's purpose. The PSUR should replace the need for a final PASS report.

Question 10 of 10 For an imposed non-interventional PASS, why may a substantial amendment require specific regulatory handling in addition to internal protocol change control?

Because every voluntary study is legally prohibited from amendment. Because the imposed study has a regulatory basis and applicable procedures may control substantial changes to the agreed activity. Because the RMP cannot be updated after study initiation. Because non-interventional studies do not require protocols.

Knowledge Assessment: PASS in the EU Risk Management Plan

Cookie Settings